Astrocytoma, IDH-Mutant, Grade 3 — Trials

Astrocytoma, IDH-Mutant, Grade 3 — Trials · CancerIndex

Clinical trials

Registered studies

8 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 7
Recruiting: 5
Ph III recruiting: 2
Growth YoY: —
Industry share: 29%
Top sponsor: National Cancer Institute (NCI)
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (0)

clinicaltrialsPublishedShowing 1–8 of 8 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03528642	Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma	active not recruiting	Phase 1	23	National Cancer Institute (NCI)NIH	1	Sep 22, 2026	clinicaltrials
NCT07703436	Safety and Efficacy Study of Safusidenib in Participants With IDH1-Mutant Glioma Who Discontinued Vorasidenib Treatment Due to Progressive Disease	not yet recruiting	Phase 2	40	Nuvation Bio Inc.INDUSTRY	1	Sep 22, 2026